Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. - Test2 - elhamkhani - TriplyDB

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34565132

about

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Developing strategies in the immunotherapy of leukemias Monoclonal antibodies in acute lymphoblastic leukemia Recent advances and novel treatment paradigms in acute lymphocytic leukemia Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression Burkitt lymphoma in adolescents and young adults: management challenges.Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.Aortic stiffness increases upon receipt of anthracycline chemotherapy Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.Immunotherapy in acute leukemia The combination of monoclonal antibodies and conventional chemotherapy for children with malignant lymphoma: Opportunities and challenges.Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.Burkitt's Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.Burkitt lymphoma: pathogenesis and immune evasion.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.Use of appropriate initial treatment among adolescents and young adults with cancer.Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.EBV-associated lymphomas in adults Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Proteomic analysis of exosomes derived from human lymphoma cells.The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010 Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.

P2860

Q24681992-8264929A-05D4-4D83-9497-A082942FE504 Q26746934-E2967AE4-2851-4943-B950-4A26376C09E0 Q26996310-53911E06-5B79-47FE-AEE1-9B12DAD5D5BC Q27022540-4CC9F75E-E20E-4E9F-BA63-710EF4D698DC Q28078076-701E41F2-C213-4FE1-B103-4269DB739CE5 Q28478132-FDD2DC68-886F-4BEE-BD26-A4A6AB3577F6 Q30238965-34C260C5-74F4-4267-9F8E-D04998E94E46 Q30243925-1CB4C827-7C93-43C5-867D-7A064944AC75 Q30252776-6E7F5EC6-EB88-44FD-8AA2-8320617A324E Q30540646-B68C789B-15BD-459D-88CF-C75BABF52E7C Q33382073-3A149DB7-F4D0-4F1A-80DB-4E335CF9CC08 Q33411059-CFE54F60-D901-4F4D-BAA3-F9B6417024B1 Q33425087-D2312BCE-7360-40E4-8C51-BEBCD38907CC Q33561937-16D74087-38AE-4A2F-8059-C4AD20A3BA12 Q33632278-15934092-7B1F-4D51-99A1-BE0A8A9FE303 Q33731552-EA5551E2-AD76-4D6C-9131-E4632518B8A8 Q33802550-2F529C93-B74D-4C85-BBF0-C921FA1215EA Q33806007-B793D464-D6F9-4977-9A11-16C11467C67B Q33859497-6AAA525C-6315-446A-8019-66E015C75FAB Q33915990-1897F243-7394-4AD7-9BCA-CA0298990320 Q34018599-22E74F6C-EC07-4BED-944E-2DCA6AC3090D Q34131844-EB09D94E-0EE3-4016-80FE-1EC3782990C7 Q34146996-97F74786-CB78-44A3-956F-34A54F8F3D9A Q34189497-688324E6-7FF1-44EA-8358-C2FA9FCDB2F7 Q34202277-46E97747-A1D3-476A-B2AD-D4011F94FFDB Q34344942-F335F00E-BD44-4E08-9409-C9B97D7ECB0C Q34354175-DB5D654F-4A76-405B-AE0D-F36EB97DB351 Q34522797-E33B297F-FA36-45AA-A1CA-BBE8C30AD511 Q34627112-8B314BDB-D6E3-4718-B41B-09E01E8A3CC7 Q34636601-46917FE3-CF7E-451B-A2CD-23E4CD6C5A30 Q34646755-DA888E2E-C6D6-4033-BF25-19930D65CA56 Q34737471-26024C91-372E-4FE9-8300-C5C2D0E2D9F7 Q35083003-DB217530-8724-43C9-8710-8EC49D51B33B Q35086932-4548BAC8-73DE-48D0-957A-DFEDF67E4025 Q35087291-75E53C27-0383-4733-9833-F365DF5AF9AC Q35236068-1FE0D2FC-853B-4A6D-B44F-83252B8EC087 Q35384536-B738E00B-61FC-4D4A-A090-B32C5EF968FC Q35429833-3FA6A1E6-615E-428D-867E-9744BE202646 Q35582198-2D3A4EA3-A873-4C20-B1AD-3B544CECFE16 Q35606384-57C26E3D-261A-47A7-B86B-F7A2C492BCB9

P2860

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34565132

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@ast

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@en

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@nl

type

label

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@ast

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@en

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@nl

prefLabel

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@ast

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@en

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@nl

P1433

Q34565132-75129A48-CC5D-4014-95A4-7D13CBA62B47

P1476

Q34565132-8B144DE2-D099-46AA-9A65-2E97B55D9074

P2093

Q34565132-05A2722B-F1CE-4B0A-BD55-46BFA835E0B9

Q34565132-1D25386D-3766-42FE-99A3-FD2BA15225DB

Q34565132-7141936B-59E7-4D95-8878-2E8F2B0F6C4C

Q34565132-8A356AAD-5150-4E8E-B947-44563D07EAF6

Q34565132-A9546691-6252-417B-AF50-09544E8675D8

Q34565132-AE557ACC-2E45-4A3C-98DE-544FC27366FC

Q34565132-D95F607B-C8F6-4583-9620-5AF88E3D9DF4

Q34565132-DF1C3482-870E-4292-B584-1ED193600C7D

P304

Q34565132-A826D218-0C59-4484-9D95-8EB546CE6A44

P31

Q34565132-DF0A2623-AD1D-40FA-944E-40F856D1315C

P356

Q34565132-5FA7DBCA-4AE0-45E6-8529-02A37AA0C5AF

P407

Q34565132-DFB2A1E6-2828-45B8-B29B-EA131D2B0ADA

P433

Q34565132-5790A1BF-A2B5-4590-AA8B-4273B46D2D1E

P478

Q34565132-08434ADC-6C26-4A2C-8A27-0CF17A69487E

P50

Q34565132-018F251F-AC7E-478D-A76C-E62A12C80815

Q34565132-0A344A43-27A5-4ED5-89EA-E8663DD7E0DE

Q34565132-2062FF95-F439-455A-98D1-9443739983E0

Q34565132-2B6E10A2-116E-47BB-8F08-E2938001AD52

Q34565132-9C803695-F427-4A0B-A2EC-7D5E7B181C77

Q34565132-A8602A97-7458-4E39-9528-B52E9C049C09

Q34565132-FD0FD813-EF0F-4101-8927-F0B3B1C838A6

Q34565132-FE23A029-FD76-4D09-B96A-1557E58EBC2B

P577

Q34565132-7BB840EE-BD0A-446B-AB91-EB291BA7FE97

P5875

Q34565132-167C671D-86EA-445B-9738-F456D467667B

P698

Q34565132-9AEADFF2-2207-4828-B68C-FB5EB13991BF

P921

Q34565132-266F1E70-1CB0-43BB-86A1-0E87417D273B

Q34565132-EA6CFD3D-E074-430B-BF5C-F5B4EDB941B0

P356

P1433

P1476

Chemoimmunotherapy with hyper- ...... acute lymphoblastic leukemia.

@en

P2093

Carlos Bueso-Ramos

http://www.w3.org/2001/XMLSchema#string

Deborah A Thomas

http://www.w3.org/2001/XMLSchema#string

Fernando Cabanillas

http://www.w3.org/2001/XMLSchema#string

Francis J Giles

http://www.w3.org/2001/XMLSchema#string

Fredrick B Hagemeister

http://www.w3.org/2001/XMLSchema#string

Jianqin Shan

http://www.w3.org/2001/XMLSchema#string

Mark Brandt

http://www.w3.org/2001/XMLSchema#string

Sherry A Pierce

http://www.w3.org/2001/XMLSchema#string

P304

1569-1580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.21776

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

William G Wierda

Srdan Verstovsek

Guillermo Garcia-Manero

Michael J. Keating

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7275989

http://www.w3.org/2001/XMLSchema#string

P698

16502413

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma